6-K

                                   FORM 6-K

                      SECURITIES AND EXCHANGE COMMISSION

                           Washington, D.C.   20549

                           REPORT OF FOREIGN ISSUER
                     Pursuant to Rule 13a-16 or 15d-16 of
                      the Securities Exchange Act of 1934

                            Dated January 14, 2000

                   PHOENIX INTERNATIONAL LIFE SCIENCES INC.
                   ----------------------------------------
                (Translation of registrant=s name into English)

                               2350 Cohen Street
                               -----------------
                     Saint Laurent, Quebec Canada H4R 2N6
                     ------------------------------------
                   (Address of principal executive offices)

     Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.

          Form 20-F    ______    Form 40-F    X   (commenced in calendar
                                            -----
                                                         year 1998)

     Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

               Yes ____      No   X
                                 ---

     If  "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): ______________



                                 SIGNATURES


     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.


                         PHOENIX INTERNATIONAL LIFE SCIENCES INC.
                         ----------------------------------------
                                (Registrant)


Date:  January 14, 2000    By: /s/ David Moszkowski
       ----------------       -----------------------------
                                    David Moszkowski
                                    Senior Vice President and
                                    Chief Financial Officer

EX-99.1

                                                                    EXHIBIT 99.1
                                                                    ------------
                                                           For immediate release

                         PHOENIX INTERNATIONAL APPOINTS
                 SENIOR VICE PRESIDENT PHASE I - NORTH AMERICA

MONTREAL, QUEBEC - JANUARY 11TH, 2000 - Phoenix International Life Sciences Inc.
(NASDAQ: PHXI; TSE: PHX) today announced the appointment of Gerald J. Merritt,
MS, PharmD, as Senior Vice President Phase I - North America. In this new
position, Mr. Merritt will be responsible for establishing the strategy related
to all activities of Phoenix's Phase I Operation in North America. In
particular, Mr. Merritt will direct and oversee the company's Phase I operations
in Cincinnati, as well as plan, develop and implement a First-in-Man (FIM)
clinic in Montreal once the Canadian regulations are favorable to this new
business.

"We are delighted to welcome Mr. Merritt to Phoenix. He is an accomplished
manager, researcher and problem solver with extensive clinical experience. He
directed one of the most successful global Phase I units and that will
undoubtedly help us achieve our goal, which is to maximize profit in all
operations," said Dr. Stephane Huguet, President and COO Global Analytical and
Phase I Services.

Mr. Merritt comes to Phoenix from PPD Development in Austin, Texas, where he
worked as Executive Director, Clinics North America. Prior to that, he held the
following positions: Chief of Clinical Investigations and Life Sciences, United
States Air Force (USAF), Washington, DC; Director of Clinical Investigation
Facility, David Grant Medical Center in Fairfield, CA; Chief of Clinical
Pharmacy Services at Wilford Hall Medical Center, in San Antonio, Texas; Chief
of Inpatient & Clinical Pharmacy Services, David Grant Medical Center in
Fairfield, CA; Chief of Drug Information and Inpatient Pharmacy Services at the
Malcolm Grow Medical Center in Washington, DC.

"This is an exiting opportunity. Phoenix is a world leader in early stage
pharmaceutical development and has clearly defined growth objectives. I look
forward to making a strong contribution as part of the Phoenix management team,
" said Mr. Merritt.

Mr. Merritt obtained his Doctorate of Pharmacy (with an emphasis in adult
medicine and pharmacokinetics) at the University of Texas, in 1983, and his
Master of Science in Pharmacy (with an emphasis in drug information) at the
University of North Carolina, in 1976. His achievements in research and clinical
services are numerous: he managed three high revenue research clinics with over
300 beds and more than 250 staff. He developed and directed USAF's first drug
information center and the most comprehensive clinical pharmacy service at a
1000 bed medical center, where he worked with over 90 pharmacy staff, 450
physicians and 1000 nurses. He also directed the USAF's multi-million dollar
biomedical research program while reviewing over 400 research protocols per
year, as well as establishing and managing the USAF's third clinical research
facility. Mr. Merritt has served as the key link between U.S. and NATO allies
for aeromedical research, leading a team of over 30 U.S. scientists to present
papers and develop standards at an international level. He has to his credit 11
peer-reviewed publications and 35 professional presentations.


Over the years, Mr. Merritt has been the recipient of various prestigious
awards, including the United States Air Force Outstanding Pharmacist; The Legion
of Merit, Joint Service Commendation Medal, and five Meritorious Service Medals
for developing innovative pharmacy and research programs. He also engages in
community activities and has served as Chairman of the Board for the American
Diabetes Association and the American Pharmaceutical Association.

ABOUT PHOENIX INTERNATIONAL

Phoenix International is one of the world's leading contract research
organizations. The company is a global leader in early stage pharmaceutical
development and has a growing presence in late stage pharmaceutical development.
Headquartered in Montreal, Quebec, Phoenix International employs over 2,000
people in 19 countries around the world. Phoenix International is on the
worldwide web at www.pils.com.


FOR MORE INFORMATION, PLEASE CONTACT:

Richard Gareau, Director of Communications
Phoenix International Life Sciences Inc.
Tel: (514) 333-0033, extension 4638
E-mail: richard.gareau@pils.com